Step 1
Evidence
Does the therapy work well enough, and for whom?
Check the clinical evidence, safety profile, and trial pipeline that determine whether a therapy can credibly move toward care.
Explore The ScienceRoad to Access
From clinical promise to patient access
Psychedelic therapies are moving toward healthcare systems. Clinical approval does not guarantee patient access.
Access depends on evidence, regulation, reimbursement, delivery readiness, and equity. Breakdowns at any stage can prevent therapies from reaching the people who need them.
ICPR 2026 talk
Watch the conference talk behind the access roadmap
Floris Wolswijk walks through the four gates between a European licence and real patient access: assessment, payment, delivery, and the implementation work needed before treatment reaches people like Marieke.
Video, slides, and slide text
Are reimbursement pathways ready for licensed psychedelic therapies in Europe?
This page pairs the YouTube recording with the full slide deck, slide-by-slide text, and links into related Road to Access guides.
Start here
Pick the access question closest to your work. Each route opens into the same full library below.
The five gates between approval and access
Use the Road to Access as a sequence. Science starts the case, but reimbursement, delivery, and equity decide whether the system can actually make care available.
Step 2
Approval
Can regulators authorize it for medical use?
Follow the approval pathways, regulatory designations, and policy decisions that decide whether evidence becomes a legal treatment option.
Explore Regulatory PathwaysStep 3
Reimbursement
Who pays, and under what evidence standard?
Understand health technology assessment, coverage decisions, economic evidence, and payer logic that determine whether patients can afford care.
Explore Who PaysStep 4
Delivery
Can the health system deliver it safely at scale?
Look at care models, workforce needs, training, infrastructure, and operational bottlenecks that shape real-world delivery.
Explore Solutions & ModelsStep 5
Access
Who actually receives care, and who is left out?
Track affordability, equity, underserved populations, and global access questions that determine whether implementation is fair.
Explore Access & EquityExplore the full library
The guided path gives you the sequence; the library gives you the depth. Use Big Picture when you want the synthesis after checking evidence, approval, payment, delivery, and equity.
Step 1: Evidence
The Science
Clinical evidence, trial design, follow-up, safety, and the study choices that shape later access decisions.
2 Apr 2026Reimbursement Report
Clinical Development of Psychedelic Therapies
How psychedelic trial design choices shape approval, HTA review, reimbursement, service delivery, and patient access.
GuideThe Science
Trial Follow-Up vs HTA Horizon
A visual explanation of why pivotal endpoints, observed follow-up, and HTA model horizons answer different questions for high-touch psychedelic therapies.
Open guide
GuideThe Science
Trial Design Choices That Become Access Risks
A practical map of the protocol choices that can support approval while still leaving payer, delivery, or access questions unresolved.
Open guide
Step 2: Approval
Regulatory Pathways
Regulatory approval, scheduling, special access, and country-level rules that decide whether a therapy can be used medically.
Step 3: Reimbursement
Who Pays
HTA, payer evidence, reimbursement models, pricing, and payment design for drug-plus-therapy care.
29 May 2026
The Personnel-Hours Question in Psychedelic Therapy
A practical guide to staff-hours in psychedelic therapy, and why protocol design, role mix, country rules, and workforce capacity shape cost and access.
24 Apr 2026
Payer Evidence Checklist for Psychedelic Therapies
The evidence payers and HTA bodies need before psychedelic therapies can move from promising trials to coverage decisions.
17 Apr 2026
Psychedelic Therapy Access in Europe: Comparison
Compare ketamine and esketamine licensing, reimbursement, and practical service availability across selected European markets.
17 Apr 2026
EU and UK HTA in 2026: Implications for reimbursement readiness
How EU HTA coordination and UK methods updates affect reimbursement strategy, service-cost modelling, and launch readiness for psychedelic therapies.
2 Apr 2026Reimbursement Report
Payer and Health Technology Assessments
What payers and HTA bodies need to know before psychedelic therapies can be covered and delivered.
2 Apr 2026Reimbursement Report
Reimbursement Landscape in Europe
How European reimbursement systems differ, and why national payment decisions shape access after EMA approval.
GuideWho Pays
Europe Access Clocks
Explains the time gap between EMA authorization and real access or reimbursement, using country-level WAIT benchmarks and scenario controls.
Open guide
GuideWho Pays
Netherlands HTA Access Clock
A Netherlands-specific explainer for the handoff from EMA authorization to ZiN assessment, possible sluis placement, NZa payment design, and practical access.
Open guide
GuideWho Pays
Psilocybin HTA Uncertainties
A payer-facing map of the clinical, economic, and implementation uncertainties that remain even when psilocybin-assisted therapy shows a positive clinical endpoint.
Open guide
GuideWho Pays
Psychedelic Therapy Payment Bundle
A service-component map and interactive payment model for reimbursing the medicine, dosing day, therapist time, monitoring, registry work, and follow-up.
Open guide
GuideWho Pays
Psychedelic Therapy Cost-Effectiveness Model
A reusable cost-utility, cost-effectiveness, and cost-benefit engine for psychedelic-assisted therapy, with illustrative parameter packs, evidence-status labels, and country HTA lenses.
Open guide
GuideWho Pays
Spravato Access Precedent
A comparator resource for how esketamine moved from EU authorization into different national access outcomes, and what that teaches for psilocybin-assisted therapy.
Open guide
GuideWho Pays
Real-World Evidence and Registry Design
A registry-design resource for the post-approval evidence questions that trials and economic models rarely settle on their own.
Open guide
GuideWho Pays
Group Therapy Economics and Implementation
A first-pass resource on when group formats may improve access, when they may add governance burden, and how payment and evidence questions change.
Open guide
Talk resourceWho Pays
Are Reimbursement Pathways Ready for Licensed Psychedelic Therapies in Europe?
ICPR 2026 talk page with the recording, downloadable slides, slide-by-slide text, and links into Road to Access guides.
Open guide
Step 4: Delivery
Solutions & Models
Delivery models, workforce plans, payment bundles, registries, training, and practical ways to make psychedelic therapy easier to implement.
17 Apr 2026
PsyPal 2026: What the guidance changes for implementation strategy
A practical synthesis of the 2026 PsyPal guidance for psychedelic therapy implementation, access planning, service design, and payer readiness.
2 Apr 2026Reimbursement Report
Potential Reimbursement and Access Pathways
Nine routes that could shape psychedelic therapy access, from ordinary reimbursement to pilots, private payment, special access, and managed entry.
2 Apr 2026Reimbursement Report
Solutions and Recommendations
Practical recommendations for evidence generation, payment design, regulation, delivery infrastructure, and equitable access.
GuideSolutions & Models
Netherlands Psilocybin Access Sites
A map of current Dutch COMP006 trial sites and plausible implementation infrastructure for a future psilocybin-assisted treatment pathway.
Open guide
GuideSolutions & Models
Netherlands Psychedelic Therapy Workforce
A Dutch workforce-readiness page and scenario model for turning BIG-registered professionals into practical psychedelic-therapy capacity.
Open guide
GuideSolutions & Models
Psychedelic Therapy Launch-Readiness Checklist
A practical Road to Access checklist for turning a positive clinical and regulatory path into reimbursed, governed, and deliverable psychedelic-assisted therapy.
Open guide
GuideSolutions & Models
Clinical Delivery Model for Psychedelic Therapy
A governed clinical pathway for psychedelic therapy, from referral and screening through dosing-day care, follow-up, escalation, and outcome reporting.
Open guide
GuideSolutions & Models
Referral, Screening, and Triage Pathway
A patient-entry pathway showing how someone can be referred, screened, treated, deferred, redirected, or followed after psychedelic therapy.
Open guide
GuideSolutions & Models
Training and Credentialing for Psychedelic Therapy
A governance resource separating training, credentialing, supervision, fidelity monitoring, professional authorization, and site accountability.
Open guide
Supporting context for Delivery
Barriers & Challenges
The evidence, policy, workforce, infrastructure, stigma, and system constraints that can slow implementation after approval.
Step 5: Access
Access & Equity
Who can reach care, who is excluded by cost or design, and how access models can avoid repeating existing mental-health inequities.
17 Apr 2026
Comparative access pathways: Oregon, Canada and Australia
A practical comparison of Oregon, Canada, and Australia access pathways, and what they show about legal permission, payment, scale, and equity.
2 Apr 2026Reimbursement Report
Ensuring Equitable Access
How cost, geography, language, cultural trust, referral rules, and trial representation shape who can receive psychedelic therapy.
GuideAccess & Equity
Clinical Care vs Retreat Pathways
A scenario resource for Marieke's access choices: clinical care, trials, private specialist care, retreat access, self-directed use, or waiting in standard care.
Open guide
Overview / synthesis
The Big Picture
A synthesis of the access pathway: evidence, approval, reimbursement, delivery, and equity across Europe, the US, and early access markets.
2 Apr 2026Reimbursement Report
Critical Observations from Collaborators
Stakeholder perspectives on commercial strategy, reimbursement, workforce capacity, advocacy, and country-level implementation for psychedelic therapies in Europe.
2 Apr 2026Reimbursement Report
Introduction to Psychedelics and Reimbursement
A plain-language introduction to why psychedelic therapy access depends on reimbursement, service design, trained staff, and country-level payment decisions.
2 Apr 2026Reimbursement Report
Reimbursement Pathways for Psychedelic Therapies: An Overview
A practical overview of why psychedelic therapy reimbursement is difficult, which access barriers matter most, and what needs to be solved before patients can receive care.
GuideThe Big Picture
Country Launch-Readiness Scorecard Methodology
How Blossom reads country-level evidence, access, reimbursement, delivery, ecosystem, and source-review signals when interpreting launch readiness.
Open guide